{"id":"agn-195263-0-03","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL4303670","moleculeType":"Small molecule","molecularWeight":"424.57"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Glucagon receptor antagonists work by blocking the action of glucagon, a hormone that raises blood glucose levels. By inhibiting glucagon, AGN-195263 aims to lower blood glucose levels in patients with diabetes.","oneSentence":"AGN-195263 is a glucagon receptor antagonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:20:12.391Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT01633788","phase":"PHASE2","title":"A Study of AGN-195263 for the Treatment of Meibomian Gland Dysfunction","status":"COMPLETED","sponsor":"Allergan","startDate":"2012-08-22","conditions":"Meibomian Gland Dysfunction","enrollment":232}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":267593,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AGN-195263 0.03%","genericName":"AGN-195263 0.03%","companyName":"Allergan","companyId":"allergan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AGN-195263 is a glucagon receptor antagonist. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}